Skip Navigation LinksHome > April 2013 - Volume 56 - Issue 4 > Preoperative Infliximab Therapy Does Not Increase Morbidity...
Diseases of the Colon & Rectum:
doi: 10.1097/DCR.0b013e3182759029
Original Contribution: Inflammatory Bowel Disease

Preoperative Infliximab Therapy Does Not Increase Morbidity and Mortality After Laparoscopic Resection for Inflammatory Bowel Disease

Krane, Mukta K. M.D.; Allaix, Marco E. M.D.; Zoccali, Marco M.D.; Umanskiy, Konstantin M.D.; Rubin, Michele A. R.N., A.P.N., C.N.S.; Villa, Anthony R.N., A.P.N., N.P.; Hurst, Roger D. M.D.; Fichera, Alessandro M.D.

Collapse Box

Abstract

BACKGROUND: The impact of infliximab on the postoperative course of patients with IBD is under debate.

OBJECTIVE: The aim of this study was to evaluate the influence of infliximab on perioperative outcomes in patients undergoing elective laparoscopic resection for IBD.

DESIGN: This study is a retrospective analysis of a prospectively collected, institutional review board-approved database.

SETTING, PATIENTS, INTERVENTIONS: Patients undergoing laparoscopic resection on preoperative infliximab (infliximab group) were compared with patients who did not receive infliximab (noninfliximab group).

MAIN OUTCOME MEASURES: The short-term and long-term morbidity and mortality rates were assessed.

RESULTS: Elective laparoscopic resection for IBD was performed on 518 patients from January 2004 through June 2011; 142 patients were treated with infliximab preoperatively. Both groups had similar demographics, type and severity of IBD, comorbidities, and type of surgery. A significantly higher number of patients in the infliximab group had been on aggressive medical therapy to control symptoms of IBD during the month preceding surgery, including steroids (73.9 vs 58.8%, p = 0.002) and immunosuppressors (32.4 vs 20.5%, p = 0.006). Operative time and blood loss were similar (p = 0.50 and p = 0.34). Intraoperative complication rate was 2.1% in both groups. No significant differences were observed in terms of the conversion rate to laparotomy (6.3% vs 9.3%, p = 0.36), overall 30-day postoperative morbidity (p = 0.93), or mortality (p = 0.61). The rates of anastomotic leak (2.1% vs 1.3%, p = 0.81), infections (12% vs 11.2%, p = 0.92), and thrombotic complications (3.5% vs 5.6%, p = 0.46) were similar. Subgroup analyses confirmed similar rates of overall, infectious, and thrombotic complications regardless of whether patients had ulcerative colitis or Crohn’s disease.

LIMITATIONS: This study is subject to the limitations of a retrospective design.

CONCLUSIONS: Infliximab is not associated with increased rates of postoperative complications after laparoscopic resection.

© The ASCRS 2013

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.